Biopharma firm DBV Technologies SA's (NASDAQ:DBVT) submission of BLA (biologics license application to the US FDA) for its VIASKIN peanut patch in children remains on track for the first half of this year, according to Guggenheim Securities.

The DBV Technologies Analyst: Analyst Yatin Suneja maintained a Buy rating and price target of $51.

The DBV Technologies Thesis: The company reported a net loss of around $147 million, or $1.05 per share, for fiscal 2025, Suneja said in the note.

Check out other analyst stock ratings.

DBV Technologies exited the year with a cash position of around $284 million, which could provide it with a runway into the second quarter of 2027, he added.

With the FDA recently highlighting "the severe unmet need for pediatric food allergies," the company's BLA submission for its VIASKIN peanut patch in children has "potential for priority review," the analyst stated.

DBV Technologies expects to make a BLA submission for toddlers by the second half of the year, he further said.

"We expect approval for both children & toddlers, and we anticipate swift uptake of VIASKIN peanut patch," Suneja further wrote.

DBVT Price Action: DBV Technologies shares were down 0.69% at $20.07 at the time of publication on Friday, according to Benzinga Pro data.

Photo: Shutterstock